TWI528961B - 作為聚（ａｄｐ-核糖）聚合酶（ｐａｒｐ）抑制劑之經醯胺取代之吲唑 - Google Patents

作為聚（ａｄｐ-核糖）聚合酶（ｐａｒｐ）抑制劑之經醯胺取代之吲唑 Download PDF

Info

Publication number
TWI528961B
TWI528961B TW097100730A TW97100730A TWI528961B TW I528961 B TWI528961 B TW I528961B TW 097100730 A TW097100730 A TW 097100730A TW 97100730 A TW97100730 A TW 97100730A TW I528961 B TWI528961 B TW I528961B
Authority
TW
Taiwan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
tautomer
phenyl
Prior art date
Application number
TW097100730A
Other languages
English (en)
Chinese (zh)
Other versions
TW200836731A (en
Inventor
強森 飛利浦
瑪利亞 歐托利 歐托利 傑瑟斯
史卡沛利 瑞塔
史奇特茲 福得莫奇 卡史單
Original Assignee
Ｍｓｄ義大利公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37809722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI528961(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ｍｓｄ義大利公司 filed Critical Ｍｓｄ義大利公司
Publication of TW200836731A publication Critical patent/TW200836731A/zh
Application granted granted Critical
Publication of TWI528961B publication Critical patent/TWI528961B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW097100730A 2007-01-10 2008-01-08 作為聚（ａｄｐ-核糖）聚合酶（ｐａｒｐ）抑制劑之經醯胺取代之吲唑 TWI528961B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0700432.8A GB0700432D0 (en) 2007-01-10 2007-01-10 Therapeutic compounds
US92131007P 2007-04-02 2007-04-02

Publications (2)

Publication Number Publication Date
TW200836731A TW200836731A (en) 2008-09-16
TWI528961B true TWI528961B (zh) 2016-04-11

Family

ID=37809722

Family Applications (1)

Application Number Title Priority Date Filing Date
TW097100730A TWI528961B (zh) 2007-01-10 2008-01-08 作為聚（ａｄｐ-核糖）聚合酶（ｐａｒｐ）抑制劑之經醯胺取代之吲唑

Country Status (21)

Country Link
CN (1) CN101578279B (da)
AT (1) ATE502933T1 (da)
CR (1) CR10910A (da)
DE (1) DE602008005711D1 (da)
DK (2) DK2336120T3 (da)
ES (3) ES2728199T3 (da)
GB (1) GB0700432D0 (da)
HN (1) HN2009001260A (da)
HU (1) HUE044513T2 (da)
LT (1) LT2805945T (da)
LU (1) LUC00072I2 (da)
ME (1) ME03481B (da)
MY (1) MY147789A (da)
NI (1) NI200900135A (da)
NZ (1) NZ578256A (da)
PE (1) PE20081558A1 (da)
PT (3) PT2109608E (da)
SI (2) SI2109608T1 (da)
TW (1) TWI528961B (da)
UA (1) UA97658C2 (da)
ZA (1) ZA200903898B (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106496187A (zh) * 2016-09-14 2017-03-15 陕西科技大学 一种制备PARP抑制剂Niraparib的合成方法
CN106432187A (zh) * 2016-09-17 2017-02-22 青岛云天生物技术有限公司 2‑[4‑(‑3‑哌啶基)苯基]‑2h‑吲唑‑7‑甲酰胺的手性拆分方法
CN106432188A (zh) * 2016-09-17 2017-02-22 青岛辰达生物科技有限公司 一种抗癌药2‑[4‑((3s)‑3‑哌啶基)苯基]‑2h‑吲唑‑7‑甲酰胺的制备方法
CN106632244A (zh) * 2016-09-30 2017-05-10 陕西科技大学 一种制备抗癌药物Niraparib的新型合成方法
CN106467513A (zh) * 2016-09-30 2017-03-01 陕西科技大学 一种制备Niraparib的合成方法
CN108201537A (zh) * 2016-12-16 2018-06-26 苏州苏融生物医药有限公司 一种尼拉帕尼缓控释药物组合物及其用途
KR20190130625A (ko) * 2017-03-27 2019-11-22 테사로, 인코포레이티드 니라파립 제제
CN109081828B (zh) * 2017-06-14 2021-03-26 上海时莱生物技术有限公司 聚(adp-核糖)聚合酶抑制剂、制备方法及用途
CA3076907A1 (en) 2017-09-26 2019-04-04 Tesaro, Inc. Niraparib formulations
CN108084157A (zh) * 2018-02-12 2018-05-29 安庆奇创药业有限公司 一种尼拉帕尼的合成方法
CN108203404A (zh) * 2018-03-02 2018-06-26 上海博邦医药科技有限公司 (r)-3-苯基哌啶或/和(s)-3-苯基哌啶以及尼拉帕尼的手性中间体的合成方法
US20240016775A1 (en) 2020-02-24 2024-01-18 Fukang (Shanghai) Health Technology Co., Ltd Anti-coronavirus application of poly adp ribose polymerase inhibitor
CN115611860B (zh) * 2021-07-13 2024-06-11 上海博璞诺科技发展有限公司 合成尼拉帕尼的方法

Also Published As

Publication number Publication date
LT2805945T (lt) 2019-06-25
TW200836731A (en) 2008-09-16
ATE502933T1 (de) 2011-04-15
PT2109608E (pt) 2011-05-30
NZ578256A (en) 2011-12-22
GB0700432D0 (en) 2007-02-21
CN101578279A (zh) 2009-11-11
SI2109608T1 (sl) 2011-07-29
DE602008005711D1 (de) 2011-05-05
LUC00072I2 (fr) 2018-07-04
MY147789A (en) 2013-01-31
CR10910A (es) 2010-01-19
HUE044513T2 (hu) 2019-10-28
ES2509115T3 (es) 2014-10-17
ME03481B (me) 2020-01-20
UA97658C2 (ru) 2012-03-12
ZA200903898B (en) 2010-04-28
PT2336120E (pt) 2014-10-01
DK2109608T3 (da) 2011-07-11
HN2009001260A (es) 2012-03-26
PE20081558A1 (es) 2008-10-30
ES2728199T3 (es) 2019-10-22
PT2805945T (pt) 2019-06-06
SI2336120T1 (sl) 2014-10-30
NI200900135A (es) 2010-08-30
ES2362214T3 (es) 2011-06-29
DK2336120T3 (da) 2014-10-06
CN101578279B (zh) 2013-07-17

Similar Documents

Publication Publication Date Title
TWI528961B (zh) 作為聚（ａｄｐ-核糖）聚合酶（ｐａｒｐ）抑制劑之經醯胺取代之吲唑
US8071623B2 (en) Amide substituted indazoles as poly(ADP-ribose)polymerase(PARP) inhibitors
JP5989965B2 (ja) ２−｛４−［（３ｓ）−ピペリジン−３−イル］フェニル｝−２ｈ−インダゾール−７−カルボキサミドの薬学的に許容される塩
US8354413B2 (en) Quinolin-4-one and 4-oxodihydrocinnoline derivatives as inhibitors of poly(ADP-ribose) polymerase (PARP)
IL205142A (en) Pyridinone derivatives, their use in curing and the pharmaceutical composition containing them
TWI522352B (zh) 醯胺基取代的吲唑衍生物類聚（ａｄｐ－核糖）聚合酶抑制劑